Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Shares Outstanding (2016 - 2025)

VYNE Therapeutics' Shares Outstanding history spans 10 years, with the latest figure at $33.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 124.7% year-over-year to $33.3 million; the TTM value through Dec 2025 reached $33.3 million, up 124.7%, while the annual FY2025 figure was $33.3 million, 124.7% up from the prior year.
  • Shares Outstanding reached $33.3 million in Q4 2025 per VYNE's latest filing, up from $19.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $53.5 million in Q3 2021 to a low of $3.0 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $17.0 million, with a median of $14.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: plummeted 93.97% in 2022, then surged 346.37% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $3.0 million in 2021, then grew by 8.51% to $3.2 million in 2022, then surged by 336.54% to $14.1 million in 2023, then increased by 5.19% to $14.8 million in 2024, then skyrocketed by 124.7% to $33.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Shares Outstanding are $33.3 million (Q4 2025), $19.8 million (Q2 2025), and $16.0 million (Q1 2025).